Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.
Saved in:
| Title: | Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party. |
|---|---|
| Authors: | Duque-Afonso J; Department of Hematology/Oncology, Faculty of Medicine, University of Freiburg Medical Center, Freiburg, Germany. jesus.duque.afonso@uniklinik-freiburg.de., Finke J; Department of Hematology/Oncology, Faculty of Medicine, University of Freiburg Medical Center, Freiburg, Germany., Ngoya M; EBMT Statistical Unit, INSERM UMRs 938, Hôpital Saint Antoine, Paris, France., Galimard JE; EBMT Statistical Unit, INSERM UMRs 938, Hôpital Saint Antoine, Paris, France., Schetelig J; Medical Department I, (Hematology, Oncology and Palliative Care), University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany., Eder M; Department of Haematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Rösler W; Department of Internal Medicine 5, University Hospital Erlangen, Erlangen, Germany., Bug G; Department of Medicine 2, Goethe University, Frankfurt am Main, Germany., Neubauer A; Department for Hematology/Oncology and Immunology, University Hospital Giessen and Marburg, Campus Marburg, Philipps Universität Marburg, Marburg, Germany., Edinger M; Department of Hematology and Oncology, University of Regensburg, Regensburg, Germany., Wulf GG; Department of Hematology and Medical Oncology, University Hospital Goettingen, Goettingen, Germany., Jindra P; Department of Hematology/Oncology, Charles University Hospital, Pilsen, Czech Republic., Einsele H; Medical Department II, University Hospital Wuerzburg, Wuerzburg, Germany., Stelljes M; Department of Hematology/Oncology, University of Muenster, Muenster, Germany., Selleslag D; Department of Hematology, A.Z. Sint-Jan, Brugge, Belgium., Wagner-Drouet EM; Department of Hematology and Oncology, University Medical Center Mainz, Mainz, Germany., Bunjes D; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany., Spyridonidis A; Division of Internal Medicine I, University Hospital of Patras, Patras, Greece., Brissot E; Department of Haematology, Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France., Nagler A; Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel., Ciceri F; IRCCS San Raffaele Scientific Institute, University Vita-Salute, Milan, Italy., Mohty M; Department of Haematology, Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France. mohamad.mohty@inserm.fr. |
| Source: | Bone marrow transplantation [Bone Marrow Transplant] 2025 Mar; Vol. 60 (3), pp. 373-379. Date of Electronic Publication: 2024 Dec 19. |
| Publication Type: | Journal Article; Comparative Study; Multicenter Study |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5365 (Electronic) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
